Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant
By Denny Jacob
Clinical-stage company Pharvaris said the U.S. Food and Drug Administration lifted the clinical hold on the investigational new drug application for deucrictibant for the prophylactic treatment of hereditary angioedema attacks following a review of data from a study.
"The lift of the clinical hold in the U.S. enables us to progress the global development of deucrictibant for long-term prophylaxis," including a resumed Phase 2 study in the U.S., said Chief Executive Berndt Modig.
The FDA placed clinical studies of deucrictibant on hold in August 2022.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 22, 2024 07:20 ET (12:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst